Dr. Danial Schecter is the Co-Owner and  brainchild behind “Cannabinoid Medical Clinic”, a superchain series of clinics that specializes in the niche of assessing the prescription of cannabinoid-based medicinal treatments to patients that are referred only, no exceptions. There are currently ten clinics at the moment operating across Canada, from bustling Toronto to windy Edmonton. The expansion is on, as Canabo Medical recently went public on the Toronto Stock Exchange (Venture). As far as Dr. Schecter is concerned, it wouldn’t be a far fetched thing to say if I called him the encyclopedia of medicinal marijuana.

He first learned about cannabinoid medicine at the University of Montreal. He trained shoulder-to-shoulder with some of the brightest academias in the field of medicinal marijuana in Canada. Therefore, I also come to the conclusion, that it would be just right to call him an expert in this field.

It’s not just about his background, but the positive results he’s clocking in for Cannabinoid Medical Clinics.  As for business? It’s booming. Dr. Danial highlighted in an interview to lift that he on average sees 6 new patients and 18 follow ups on a regular day. Take into account the consultation fees for all 10 operating clinics and incoming clinics nationwide across Canada, with the patient number and follow up in mind, things are looking good for senior management. That very senior management is set to exploit an untapped niche in Canada. The reason why I say untapped is based on real life lessons. We have a lot of clinics here in Toronto. Approximately 90%, or probably even more, are your typical back-door, approve everyone type alternative therapy advisers or whatever. They’re normally given a mandate to approve all. I know because I have tested a lot of dispensaries and clinics alike here in Toronto. Canabo truly sets itself apart by underlining itself as a legitimate player due to two primary factors: the fact that appointments are reference based only through a family doctor or practicioner (unlike most others here in Toronto where only profits matter) and the simple fact that it doesn’t sell the product. These two ingredients indicate a priority given to what the boys on the block like to call, ‘Big Data.’

Big Data, eh? Some people are discrediting Dr. Schecter’s vast experience by pinning the data collection and compliance side of what Canabo is doing for the cannabis industry as something of a lie. Chris Parry called this out for what it is on Twitter, as something of a deliberate wrongdoing. I agree with him because Dr. Schecter and his team aren’t a bunch of marketers trying to sell early data and make quick profits as some would like to suggest is with the case is with most venture listed firms, though that is nothing but bullshit. They have set the bar high to focus and carve a big share in the data collection side of cannabis.

All you need to do to be convinced is simply understand the process of how the clinics operate. Remember, I have always preached simplicity when it comes to investment thesis and market psychology, and perhaps you should too. All it really takes is just a matter if due diligence. Dr. Schecter, in his interview to lift, stated, “I spend a minimum of 50 minutes with each new patient to understand what their past medical history is, what their main complaints and impairments are, what they have tried and failed in the past and understand what they are hoping to achieve by coming to the clinic.” Now that you’re a bit familiarized with the process, then you can easily answer for yourself whether Canabo is big data or not.

This data can be utilized by Canabo itself through very simple, yet lucrative solutions to important strain related questions. Leafly is a great startup, don’t get me wrong, but Canabo will have the sort of demographics, results, and information that the government and licensed producers probably can’t wait to get their hands on. Oh, I totally forgot. This data will also have answers to question Leafy won’t have, like which strain is best for which age group. That’s fucking cool.

Of course, I haven’t really gone over all of what Canabo offers because Chris Parry has already done that job. 

This is a link to Chris Parry’s article on CMM.VN (listed on the TSXV): https://www.equity.guru/2016/11/28/canabo-medical-v-cmm-a-cannabis-business-model-thats-already-far-bigger-than-you-know/

Click Here For Full Corporate Information

 

~ written by Hamzah Khan 


Pursuant to an agreement between MAPH and Canabo Medical Corp (CMM), we were hired for a period beginning November 14 2016 and ending December 14, 2016 to publicly disseminate information about (CMM) including on the Website and other media including Facebook and Twitter. We are being paid $15,000 (CASH) for or were paid “0” shares of restricted common shares. We may buy or sell additional shares of (CMM)in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please refer to full disclaimer for more information


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like